Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Oral VK2735 Phase 2 trial is currently underway ... emphasizing ongoing dialogues with global peptide suppliers to secure long-term scalability. Analysts raised questions about potential ...

Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment ...

VK2735 is a wholly owned dual agonist of the glucagon like peptide-1, or GLP-1 receptor, and the glucose dependent insulinotropic polypeptide, or GIP receptor, for the potential treatment of ...

Oral VK2735 is strategically positioned to become ... of danuglipron (PF-06882961), its twice-daily oral glucagon-like peptide-1 receptor agonist (GLP-1) candidate to treat obesity.

Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25. VK2735 is a wholly owned dual agonist of the glucagon like peptide-1, or GLP-1 receptor, and the glucose dependent ...

Reasons to buy Viking Therapeutics now It's hard to overstate the commercial success of drugs that reduce appetites by acting on glucagon-like peptide ... tentatively named VK2735, reduced obesity ...

Viking Therapeutics stock jumped higher last year because it looks like a dual GLP-1/GIP agonist it's developing could outperform tirzepatide. The injectable version of the candidate, tentatively ...